Daniel Tillett
Vermogen: 38 M $ op 31-05-2026
Vermogen: 38 M $ op 31-05-2026
Dr. Daniel Tillett is a Chief Executive Officer, MD & Director at Racura Oncology Ltd. He is on the Board of Directors at Entropy Neurodynamics Ltd. and Racura Oncology Ltd. Dr. Tillett was previously employed as a Non-Executive Director by Simble Solutions Ltd., an Executive Director & Chief Scientific Officer by Race Oncology Ltd., and a Chief Executive Officer by Nucleics Ltd. He received his undergraduate degree from School of Biotechnology & Biomolecular Sciences and a doctorate degree from School of Biotechnology & Biomolecular Sciences.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
RACURA ONCOLOGY LTD 10,64% | 28-05-2026 | 20.269.351 ( 10,64% ) | 38 M $ | 31-05-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| RACURA ONCOLOGY LTD | Algemeen Directeur | 22-11-2023 |
| Bedrijven | Functie | Einde |
|---|---|---|
| SIMBLE SOLUTIONS LIMITED | Directeur/Bestuurslid | 03-07-2023 |
| RACURA ONCOLOGY LTD | Hoofd Techniek/Wetenschap/O&O | 23-03-2023 |
Nucleics Ltd. | Algemeen Directeur | - |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 4 |
|---|---|
Race Oncology Ltd.
Race Oncology Ltd. Pharmaceuticals: MajorHealth Technology Manufactures drugs for cancer | Health Technology |
Simble Solutions Ltd.
Simble Solutions Ltd. Packaged SoftwareTechnology Services Develops software for enterprises to manage business and resources | Technology Services |
School of Biotechnology & Biomolecular Sciences
School of Biotechnology & Biomolecular Sciences Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Nucleics Ltd. |
Kies jouw editie
Alle financiële informatie op nationaal niveau